Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: r. peter Dale who wrote (134)	12/6/1997 8:54:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 579

Peter: You, of course, are not telling me anything that I don't already know. A discussion of crap-shoots, out of "market cap" context, is worthless. If you're trying to educate others in this thread, great. Sibia has, counting the conotoxin program, at least seven crap-shoot programs. The question is, how much good science, patents and screening technology can you buy for a difference between market cap and cash of $40 million? If SIBI/BMY had documented reason to believe that their lead molecules addressed the underlying cause of AD, do you think that you'd be able to buy it for $8/share with 9.3 million outstanding? Some biotech investors focus on later-stage projects where there is a high chance of success. Others put together a basket of early-stage crap-shoots which are backed by good science. Both approaches can be wildly successful. The secret to biotech investing is to place constructive criticism in a rational context. 1508Y (non-asia) and 1553A are not partnered. Thanks for the link. Rick